argenx SE (NASDAQ: ARGX) Stock Competitors & Peer Comparison

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, VRTX has a market cap of 130.8B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while VRTX trades at $515.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas VRTX's P/E ratio is 27.09. In terms of profitability, ARGX's ROE is +0.24%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ARGX is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check VRTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, REGN has a market cap of 80.5B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while REGN trades at $781.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas REGN's P/E ratio is 17.13. In terms of profitability, ARGX's ROE is +0.24%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ARGX is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check REGN's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ARGX's ROE is +0.24%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ARGX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check VRNA's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, MRNA has a market cap of 57.1B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while MRNA trades at $143.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas MRNA's P/E ratio is -17.67. In terms of profitability, ARGX's ROE is +0.24%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, ARGX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check MRNA's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, RVMDW has a market cap of 44.2B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while RVMDW trades at $11.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas RVMDW's P/E ratio is -1.28. In terms of profitability, ARGX's ROE is +0.24%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, ARGX is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check RVMDW's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, RVMD has a market cap of 43.3B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while RVMD trades at $203.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas RVMD's P/E ratio is -23.10. In terms of profitability, ARGX's ROE is +0.24%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, ARGX is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check RVMD's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ARGX's ROE is +0.24%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ARGX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check SGEN's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, ONC has a market cap of 37B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while ONC trades at $346.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas ONC's P/E ratio is 61.01. In terms of profitability, ARGX's ROE is +0.24%, compared to ONC's ROE of +0.14%. Regarding short-term risk, ARGX is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ONC's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, ALNY has a market cap of 33.3B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while ALNY trades at $248.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas ALNY's P/E ratio is 44.81. In terms of profitability, ARGX's ROE is +0.24%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, ARGX is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ALNY's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, ROIV has a market cap of 29.5B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while ROIV trades at $40.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas ROIV's P/E ratio is -38.82. In terms of profitability, ARGX's ROE is +0.24%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, ARGX is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ROIV's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, INSM has a market cap of 28B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while INSM trades at $129.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas INSM's P/E ratio is -31.49. In terms of profitability, ARGX's ROE is +0.24%, compared to INSM's ROE of -1.11%. Regarding short-term risk, ARGX is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check INSM's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, INCY has a market cap of 24.6B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while INCY trades at $121.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas INCY's P/E ratio is 16.33. In terms of profitability, ARGX's ROE is +0.24%, compared to INCY's ROE of +0.30%. Regarding short-term risk, ARGX is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check INCY's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, BNTX has a market cap of 24.3B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while BNTX trades at $96.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas BNTX's P/E ratio is -12.54. In terms of profitability, ARGX's ROE is +0.24%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, ARGX is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check BNTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, UTHR has a market cap of 21.1B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while UTHR trades at $497.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas UTHR's P/E ratio is 17.79. In terms of profitability, ARGX's ROE is +0.24%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, ARGX is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check UTHR's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ARGX's ROE is +0.24%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, ARGX is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check BGNE's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, GMAB has a market cap of 19.9B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while GMAB trades at $32.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas GMAB's P/E ratio is 24.47. In terms of profitability, ARGX's ROE is +0.24%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ARGX is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check GMAB's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ARGX's ROE is +0.24%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, ARGX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check DNA-WT's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, ASND has a market cap of 16.4B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while ASND trades at $263.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas ASND's P/E ratio is -108.89. In terms of profitability, ARGX's ROE is +0.24%, compared to ASND's ROE of +1.90%. Regarding short-term risk, ARGX is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ASND's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, NBIX has a market cap of 15.7B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while NBIX trades at $156.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas NBIX's P/E ratio is 22.57. In terms of profitability, ARGX's ROE is +0.24%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, ARGX is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check NBIX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, JAZZ has a market cap of 15.4B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while JAZZ trades at $245.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas JAZZ's P/E ratio is 9.16. In terms of profitability, ARGX's ROE is +0.24%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, ARGX is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check JAZZ's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, BBIO has a market cap of 14.2B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while BBIO trades at $72.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas BBIO's P/E ratio is -19.37. In terms of profitability, ARGX's ROE is +0.24%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, ARGX is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check BBIO's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, EXEL has a market cap of 14.1B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while EXEL trades at $56.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas EXEL's P/E ratio is 16.03. In terms of profitability, ARGX's ROE is +0.24%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, ARGX is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check EXEL's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, SMMT has a market cap of 14B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while SMMT trades at $17.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas SMMT's P/E ratio is -15.67. In terms of profitability, ARGX's ROE is +0.24%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ARGX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check SMMT's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, HALO has a market cap of 12.7B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while HALO trades at $107.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas HALO's P/E ratio is 20.00. In terms of profitability, ARGX's ROE is +0.24%, compared to HALO's ROE of +1.81%. Regarding short-term risk, ARGX is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check HALO's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, BMRN has a market cap of 12.7B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while BMRN trades at $65.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas BMRN's P/E ratio is 31.58. In terms of profitability, ARGX's ROE is +0.24%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, ARGX is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check BMRN's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ARGX's ROE is +0.24%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ARGX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check KRTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, MDGL has a market cap of 12.3B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while MDGL trades at $534.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas MDGL's P/E ratio is -41.76. In terms of profitability, ARGX's ROE is +0.24%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, ARGX is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check MDGL's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, ARWR has a market cap of 11.7B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while ARWR trades at $82.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas ARWR's P/E ratio is -36.82. In terms of profitability, ARGX's ROE is +0.24%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, ARGX is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ARWR's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, AXSM has a market cap of 11.4B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while AXSM trades at $220.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas AXSM's P/E ratio is -57.64. In terms of profitability, ARGX's ROE is +0.24%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, ARGX is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check AXSM's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while TECH trades at $72.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas TECH's P/E ratio is 37.18. In terms of profitability, ARGX's ROE is +0.24%, compared to TECH's ROE of +0.09%. Regarding short-term risk, ARGX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check TECH's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ARGX's ROE is +0.24%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ARGX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check RNAM's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, KRYS has a market cap of 10.2B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while KRYS trades at $347.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas KRYS's P/E ratio is 43.48. In terms of profitability, ARGX's ROE is +0.24%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ARGX is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check KRYS's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ARGX's ROE is +0.24%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ARGX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check RXDX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, PTGX has a market cap of 9.5B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while PTGX trades at $148.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas PTGX's P/E ratio is 143.86. In terms of profitability, ARGX's ROE is +0.24%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, ARGX is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PTGX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, KYMR has a market cap of 9.5B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while KYMR trades at $114.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas KYMR's P/E ratio is -35.92. In terms of profitability, ARGX's ROE is +0.24%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, ARGX is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check KYMR's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, PRAX has a market cap of 9.3B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while PRAX trades at $334.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas PRAX's P/E ratio is -25.88. In terms of profitability, ARGX's ROE is +0.24%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, ARGX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PRAX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, CYTK has a market cap of 9.2B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while CYTK trades at $73.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas CYTK's P/E ratio is -10.22. In terms of profitability, ARGX's ROE is +0.24%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, ARGX is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check CYTK's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ARGX's ROE is +0.24%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ARGX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check NUVL's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, IONS has a market cap of 9B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while IONS trades at $54.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas IONS's P/E ratio is -31.52. In terms of profitability, ARGX's ROE is +0.24%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ARGX is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check IONS's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while CRNX trades at $84.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas CRNX's P/E ratio is -16.86. In terms of profitability, ARGX's ROE is +0.24%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ARGX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CRNX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ARGX's ROE is +0.24%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ARGX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check IMGN's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, ABVX has a market cap of 8.7B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while ABVX trades at $118.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas ABVX's P/E ratio is -62.19. In terms of profitability, ARGX's ROE is +0.24%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ARGX is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ABVX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, TXG has a market cap of 8.7B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while TXG trades at $68.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas TXG's P/E ratio is -116.25. In terms of profitability, ARGX's ROE is +0.24%, compared to TXG's ROE of -0.09%. Regarding short-term risk, ARGX is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check TXG's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, PCVX has a market cap of 8.6B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while PCVX trades at $59.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas PCVX's P/E ratio is -7.79. In terms of profitability, ARGX's ROE is +0.24%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, ARGX is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PCVX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ARGX's ROE is +0.24%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ARGX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check BPMC's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while APGE trades at $135.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas APGE's P/E ratio is -31.19. In terms of profitability, ARGX's ROE is +0.24%, compared to APGE's ROE of -0.30%. Regarding short-term risk, ARGX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check APGE's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, IBRX has a market cap of 8.3B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while IBRX trades at $7.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas IBRX's P/E ratio is -8.15. In terms of profitability, ARGX's ROE is +0.24%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, ARGX is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check IBRX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, TGTX has a market cap of 8.2B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while TGTX trades at $53.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas TGTX's P/E ratio is 19.53. In terms of profitability, ARGX's ROE is +0.24%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, ARGX is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check TGTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas CERE's P/E ratio is -16.47. In terms of profitability, ARGX's ROE is +0.24%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ARGX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CERE's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, TWST has a market cap of 7.9B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while TWST trades at $127.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas TWST's P/E ratio is -57.31. In terms of profitability, ARGX's ROE is +0.24%, compared to TWST's ROE of -0.30%. Regarding short-term risk, ARGX is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check TWST's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, SYRE has a market cap of 7.9B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while SYRE trades at $90.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas SYRE's P/E ratio is -46.46. In terms of profitability, ARGX's ROE is +0.24%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, ARGX is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check SYRE's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, IMVT has a market cap of 7.7B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while IMVT trades at $37.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas IMVT's P/E ratio is -13.25. In terms of profitability, ARGX's ROE is +0.24%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, ARGX is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check IMVT's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ARGX's ROE is +0.24%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ARGX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check MTSR's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, RYTM has a market cap of 7.2B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while RYTM trades at $104.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas RYTM's P/E ratio is -33.67. In terms of profitability, ARGX's ROE is +0.24%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, ARGX is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check RYTM's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, BLTE has a market cap of 7B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while BLTE trades at $173.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas BLTE's P/E ratio is -92.94. In terms of profitability, ARGX's ROE is +0.24%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, ARGX is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check BLTE's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, CAI has a market cap of 6.9B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while CAI trades at $24.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas CAI's P/E ratio is 68.39. In terms of profitability, ARGX's ROE is +0.24%, compared to CAI's ROE of +0.19%. Regarding short-term risk, ARGX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check CAI's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ARGX's ROE is +0.24%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ARGX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check MRUS's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ARGX's ROE is +0.24%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ARGX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ACLX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, SRRK has a market cap of 6.6B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while SRRK trades at $55.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas SRRK's P/E ratio is -16.06. In terms of profitability, ARGX's ROE is +0.24%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, ARGX is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check SRRK's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas RETA's P/E ratio is -66.29. In terms of profitability, ARGX's ROE is +0.24%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ARGX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check RETA's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, CGON has a market cap of 6.4B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while CGON trades at $72.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas CGON's P/E ratio is -26.90. In terms of profitability, ARGX's ROE is +0.24%, compared to CGON's ROE of -0.25%. Regarding short-term risk, ARGX is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check CGON's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ARGX's ROE is +0.24%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ARGX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CNTA's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, TVTX has a market cap of 6.2B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while TVTX trades at $66.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas TVTX's P/E ratio is -147.04. In terms of profitability, ARGX's ROE is +0.24%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, ARGX is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check TVTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, MIRM has a market cap of 6B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while MIRM trades at $98.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas MIRM's P/E ratio is -6.75. In terms of profitability, ARGX's ROE is +0.24%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, ARGX is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check MIRM's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, DNTH has a market cap of 5.9B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while DNTH trades at $106.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas DNTH's P/E ratio is -25.59. In terms of profitability, ARGX's ROE is +0.24%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, ARGX is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check DNTH's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while COGT trades at $33.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas COGT's P/E ratio is -15.83. In terms of profitability, ARGX's ROE is +0.24%, compared to COGT's ROE of -0.73%. Regarding short-term risk, ARGX is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check COGT's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, LGND has a market cap of 5.7B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while LGND trades at $284.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas LGND's P/E ratio is 31.23. In terms of profitability, ARGX's ROE is +0.24%, compared to LGND's ROE of +0.20%. Regarding short-term risk, ARGX is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check LGND's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, XENE has a market cap of 5.7B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while XENE trades at $58.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas XENE's P/E ratio is -12.48. In terms of profitability, ARGX's ROE is +0.24%, compared to XENE's ROE of -0.44%. Regarding short-term risk, ARGX is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check XENE's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ARGX's ROE is +0.24%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ARGX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CDTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, ORKA has a market cap of 5.6B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while ORKA trades at $92.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas ORKA's P/E ratio is -47.62. In terms of profitability, ARGX's ROE is +0.24%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, ARGX is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ORKA's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ARGX's ROE is +0.24%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ARGX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ABCM's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while PTCT trades at $66.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas PTCT's P/E ratio is -28.35. In terms of profitability, ARGX's ROE is +0.24%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, ARGX is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PTCT's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, ERAS has a market cap of 5.5B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while ERAS trades at $15.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas ERAS's P/E ratio is -17.08. In terms of profitability, ARGX's ROE is +0.24%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, ARGX is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ERAS's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ARGX's ROE is +0.24%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ARGX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ISEE's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas APLS's P/E ratio is 38.35. In terms of profitability, ARGX's ROE is +0.24%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ARGX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check APLS's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, DFTX has a market cap of 5.2B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while DFTX trades at $38.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas DFTX's P/E ratio is N/A. In terms of profitability, ARGX's ROE is +0.24%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, ARGX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check DFTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while CRSP trades at $51.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas CRSP's P/E ratio is -10.87. In terms of profitability, ARGX's ROE is +0.24%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, ARGX is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check CRSP's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while EWTX trades at $44.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas EWTX's P/E ratio is -24.00. In terms of profitability, ARGX's ROE is +0.24%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, ARGX is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check EWTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas TERN's P/E ratio is -51.41. In terms of profitability, ARGX's ROE is +0.24%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ARGX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check TERN's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, ACAD has a market cap of 4.8B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while ACAD trades at $27.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas ACAD's P/E ratio is 12.54. In terms of profitability, ARGX's ROE is +0.24%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, ARGX is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ACAD's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ARGX's ROE is +0.24%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ARGX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check FOLD's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ARGX's ROE is +0.24%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ARGX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check AKRO's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ARGX's ROE is +0.24%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ARGX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ALPN's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, PBLS has a market cap of 4.3B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while PBLS trades at $36.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas PBLS's P/E ratio is -41.91. In terms of profitability, ARGX's ROE is +0.24%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, ARGX is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PBLS's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas OPT's P/E ratio is -1.52. In terms of profitability, ARGX's ROE is +0.24%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ARGX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check OPT's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ARGX's ROE is +0.24%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ARGX is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PRTC's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, MANE has a market cap of 4.1B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while MANE trades at $98.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas MANE's P/E ratio is -31.52. In terms of profitability, ARGX's ROE is +0.24%, compared to MANE's ROE of -0.38%. Regarding short-term risk, ARGX is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check MANE's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while RLAY trades at $18.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas RLAY's P/E ratio is -12.02. In terms of profitability, ARGX's ROE is +0.24%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, ARGX is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check RLAY's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ARGX's ROE is +0.24%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ARGX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check MRTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, CELC has a market cap of 4.1B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while CELC trades at $83.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas CELC's P/E ratio is -19.41. In terms of profitability, ARGX's ROE is +0.24%, compared to CELC's ROE of -3.51%. Regarding short-term risk, ARGX is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check CELC's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while ELVN trades at $54.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas ELVN's P/E ratio is -32.53. In terms of profitability, ARGX's ROE is +0.24%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, ARGX is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ELVN's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, ADPT has a market cap of 3.9B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while ADPT trades at $24.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas ADPT's P/E ratio is -59.02. In terms of profitability, ARGX's ROE is +0.24%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, ARGX is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ADPT's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, TNGX has a market cap of 3.9B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while TNGX trades at $23.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas TNGX's P/E ratio is -28.65. In terms of profitability, ARGX's ROE is +0.24%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, ARGX is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check TNGX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas CPRX's P/E ratio is 12.30. In terms of profitability, ARGX's ROE is +0.24%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ARGX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CPRX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, IOVA has a market cap of 3.8B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while IOVA trades at $8.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas IOVA's P/E ratio is -11.78. In terms of profitability, ARGX's ROE is +0.24%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, ARGX is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check IOVA's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while TLX trades at $11.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas TLX's P/E ratio is 117.85. In terms of profitability, ARGX's ROE is +0.24%, compared to TLX's ROE of +0.07%. Regarding short-term risk, ARGX is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check TLX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ARGX's ROE is +0.24%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ARGX is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check RYZB's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while VKTX trades at $31.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas VKTX's P/E ratio is -6.86. In terms of profitability, ARGX's ROE is +0.24%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, ARGX is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check VKTX's competition here

argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARGX stands at 61.2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ARGX is priced at $984.39 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARGX currently has a P/E ratio of 88.84, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ARGX's ROE is +0.24%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ARGX is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CBAY's competition here